Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about cte: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet. View on Wiki →
No AI portrait yet
Knowledge base pages for this entity
flowchart TD
CTE["CTE"] -->|"phosphorylates"| TAU["TAU"]
TAU["TAU"] -->|"associated with"| NEURODEGENERATION["NEURODEGENERATION"]
TAU["TAU"] -->|"activates"| NEURODEGENERATION["NEURODEGENERATION"]
TAU["TAU"] -->|"associated with"| ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
TAU["TAU"] -->|"associated with"| TAUOPATHY["TAUOPATHY"]
style CTE fill:#006494,stroke:#333,color:#e0e0e0
style TAU fill:#4a1a6b,stroke:#333,color:#e0e0e0
style NEURODEGENERATION fill:#5d2900,stroke:#333,color:#e0e0e0
style ALZHEIMER_S_DISEASE fill:#4a1a6b,stroke:#333,color:#e0e0e0
style TAUOPATHY fill:#4a1a6b,stroke:#333,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| TAU | phosphorylates | entity | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| APOE | co_associated_with | gene | 0.30 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Smartphone-Detected Motor Variability Correction | 0.742 | neurodegeneration | Digital biomarkers and AI-driven early d |
| TFAM overexpression creates mitochondrial donor-recipient gr | 0.725 | neurodegeneration | Mitochondrial transfer between astrocyte |
| Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cro | 0.642 | neurodegeneration | What are the mechanisms by which gut mic |
| Bacterial Enzyme-Mediated Dopamine Precursor Synthesis | 0.590 | neurodegeneration | What are the mechanisms by which gut mic |
| APOE4 Isoform Correction via Lipidation Enhancement as CTE R | 0.552 | neurodegeneration | What genetic risk factors predispose ind |
| H63D HFE Genotype-Guided Iron Chelation Therapy for Subset-S | 0.550 | - | Ferroptosis in ALS and motor neuron dise |
Scientific analyses that reference this entity
neuroinflammation | 2026-04-16 | 5 hypotheses Top: 0.587
neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.808
neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.703
neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.455
neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.552
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| N-of-1 Clinical Trial Design for CBS/PSP | clinical | ALS | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Experiment Scoring Methodology | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Neural Oscillation Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Levodopa Response Determinants in PSP — Biomarker-Guided Prediction St | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Prodromal Parkinson's Disease Biomarker Development — Early Detection | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for P | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Parkinson's Disease Subtype Classification — Precision Medicine Approa | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Alpha-Synuclein Seed Amplification Assay Validation | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| DLB Treatment Response Biomarkers — Predicting Cholinesterase Inhibito | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Levodopa-Induced Dyskinesias Mechanism — Experiment Design | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Wilson Disease Neurodegeneration: Mechanism and Therapeutic Response | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Selective Neuronal Vulnerability to Aging — Mapping Why Specific Neuro | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Exercise-BDNF-Mitophagy Biomarker Study in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| GLP-1 Agonist Neuroprotection Mechanism in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Synaptic Mitochondrial Resilience Enhancement for Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson' | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Cytochrome Therapeutics | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Ferroptosis Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protec | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $160,000 |
| s:** - Test MCU overexpression specifically in layer II neurons in hea | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $200,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.94 · 2026-04-16
closed · Rounds: 4 · Score: 0.70 · 2026-04-16
closed · Rounds: 4 · Score: 0.74 · 2026-04-16
closed · Rounds: 4 · Score: 0.58 · 2026-04-16
closed · Rounds: 4 · Score: 0.95 · 2026-04-16
closed · Rounds: 4 · Score: 0.95 · 2026-04-15
closed · Rounds: 4 · Score: 0.91 · 2026-04-15
closed · Rounds: 4 · Score: 0.85 · 2026-04-15
closed · Rounds: 4 · Score: 0.75 · 2026-04-15
closed · Rounds: 4 · Score: 0.85 · 2026-04-15